Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

287 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.
Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F. Park H, et al. Among authors: tsimberidou am. Oncotarget. 2016 Oct 11;7(41):67521-67531. doi: 10.18632/oncotarget.11750. Oncotarget. 2016. PMID: 27589687 Free PMC article. Clinical Trial.
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Tsimberidou AM, et al. J Clin Oncol. 2008 Jan 10;26(2):196-203. doi: 10.1200/JCO.2007.11.8513. J Clin Oncol. 2008. PMID: 18182662 Clinical Trial.
Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement.
Tsimberidou AM, Moulder S, Fu S, Wen S, Naing A, Bedikian AY, Daring S, Uehara C, Ng C, Wallace M, Camacho L, Kurzrock R. Tsimberidou AM, et al. Cancer Chemother Pharmacol. 2010 Nov;66(6):1087-93. doi: 10.1007/s00280-010-1266-4. Epub 2010 Mar 4. Cancer Chemother Pharmacol. 2010. PMID: 20204368 Free PMC article. Clinical Trial.
A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver.
Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong D, Wheler J, Bedikian AY, Eng C, Wallace M, Camacho LH, Kurzrock R. Tsimberidou AM, et al. Cancer. 2010 Sep 1;116(17):4086-94. doi: 10.1002/cncr.25277. Cancer. 2010. PMID: 20564148 Free PMC article. Clinical Trial.
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. Janku F, et al. Among authors: tsimberidou am. Mol Cancer Ther. 2011 Mar;10(3):558-65. doi: 10.1158/1535-7163.MCT-10-0994. Epub 2011 Jan 7. Mol Cancer Ther. 2011. PMID: 21216929 Free PMC article.
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R. Hong DS, et al. Among authors: tsimberidou am. J Clin Endocrinol Metab. 2011 Apr;96(4):997-1005. doi: 10.1210/jc.2010-1899. Epub 2011 Feb 2. J Clin Endocrinol Metab. 2011. PMID: 21289252 Free PMC article. Clinical Trial.
287 results